Literature DB >> 17482683

Novel strategies for inhibition of the p38 MAPK pathway.

Jiyan Zhang1, Beifen Shen, Anning Lin.   

Abstract

The p38 subgroup of the mitogen-activated protein kinase superfamily has four isoforms: p38alpha, p38beta, p38delta and p38gamma. Whereas p38alpha is involved in inflammation, proliferation, differentiation and apoptosis, the biological functions of p38beta, p38delta and p38gamma are not understood completely. Many p38alpha inhibitors with diverse chemical structures and modes of protein interaction have been designed on the basis of their ability to compete with ATP for binding to p38alpha. Although some of these inhibitors show anti-inflammatory effects in animal models, they have repeatedly failed in clinical trials, highlighting the need for better approaches to inhibitor design. Here, we discuss alternative strategies that might lead to better p38 inhibitors, including non-ATP-competitive inhibitors and inhibitors that are targeted to other components of the signaling pathway.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17482683     DOI: 10.1016/j.tips.2007.04.008

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN: 0165-6147            Impact factor:   14.819


  49 in total

1.  Development of an online p38α mitogen-activated protein kinase binding assay and integration of LC-HR-MS.

Authors:  David Falck; Jon S B de Vlieger; Wilfried M A Niessen; Jeroen Kool; Maarten Honing; Martin Giera; Hubertus Irth
Journal:  Anal Bioanal Chem       Date:  2010-08-22       Impact factor: 4.142

2.  Selective p38α MAPK deletion in serotonergic neurons produces stress resilience in models of depression and addiction.

Authors:  Michael R Bruchas; Abigail G Schindler; Haripriya Shankar; Daniel I Messinger; Mayumi Miyatake; Benjamin B Land; Julia C Lemos; Catherine E Hagan; John F Neumaier; Albert Quintana; Richard D Palmiter; Charles Chavkin
Journal:  Neuron       Date:  2011-08-11       Impact factor: 17.173

Review 3.  Unique MAP Kinase binding sites.

Authors:  Radha Akella; Thomas M Moon; Elizabeth J Goldsmith
Journal:  Biochim Biophys Acta       Date:  2007-11-19

Review 4.  Mitogen-activated protein kinases as therapeutic targets in osteoarthritis.

Authors:  Richard F Loeser; Elizabeth A Erickson; David L Long
Journal:  Curr Opin Rheumatol       Date:  2008-09       Impact factor: 5.006

5.  Disruption of TAB1/p38α interaction using a cell-permeable peptide limits myocardial ischemia/reperfusion injury.

Authors:  Qingyang Wang; Jiannan Feng; Jing Wang; Xueying Zhang; Dalin Zhang; Ting Zhu; Wendie Wang; Xiaoqian Wang; Jianfeng Jin; Junxia Cao; Xinying Li; Hui Peng; Yan Li; Beifen Shen; Jiyan Zhang
Journal:  Mol Ther       Date:  2013-07-23       Impact factor: 11.454

6.  Activation of mitogen-activated protein kinases by 5,6-dimethylxanthenone-4-acetic acid (DMXAA) plays an important role in macrophage stimulation.

Authors:  Jing Sun; Liang-Chuan S Wang; Zvi G Fridlender; Veena Kapoor; Guanjun Cheng; Lai-Ming Ching; Steven M Albelda
Journal:  Biochem Pharmacol       Date:  2011-07-26       Impact factor: 5.858

Review 7.  Seeking approval: present and future therapies for pemphigus vulgaris.

Authors:  Xuming Mao; Aimee S Payne
Journal:  Curr Opin Investig Drugs       Date:  2008-05

8.  Heat stress upregulates chaperone heat shock protein 70 and antioxidant manganese superoxide dismutase through reactive oxygen species (ROS), p38MAPK, and Akt.

Authors:  Soumyajit Banerjee Mustafi; Prabir Kumar Chakraborty; Rakhi Sharma Dey; Sanghamitra Raha
Journal:  Cell Stress Chaperones       Date:  2009-03-17       Impact factor: 3.667

Review 9.  The potential of p38 MAPK inhibitors to modulate periodontal infections.

Authors:  Keith L Kirkwood; Carlos Rossa
Journal:  Curr Drug Metab       Date:  2009-01       Impact factor: 3.731

10.  Aspirin may promote mitochondrial biogenesis via the production of hydrogen peroxide and the induction of Sirtuin1/PGC-1α genes.

Authors:  Pratibha Kamble; Krithika Selvarajan; Chandrakala Aluganti Narasimhulu; Mukesh Nandave; Sampath Parthasarathy
Journal:  Eur J Pharmacol       Date:  2012-12-07       Impact factor: 4.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.